Product image of Iclusig (Ponatinib) supplied by GNH India

Iclusig

Active Ingredient:
Ponatinib
Origin:
EU

Iclusig (Ponatinib)

Ponatinib, the active ingredient in Iclusig, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia that are resistant or intolerant to prior therapy, targeting the BCR‑ABL kinase—including the T315I mutation—and other kinases involved in tumor cell proliferation.

GNH India supplies Iclusig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑assured delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Incyte Biosciences Distribution B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iclusig (ponatinib) is used to treat malignancies driven by the BCR‑ABL tyrosine kinase pathway.

  • Chronic myeloid leukemia (CML): provides disease control in patients who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.
  • Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): offers a therapeutic option for patients with resistance or intolerance to earlier treatments.
  • BCR‑ABL positive leukemias with T315I mutation: targets the resistant mutation to restore treatment efficacy.

How It Works

  • Ponatinib inhibits the BCR‑ABL tyrosine kinase, including the gate‑keeper T315I mutation, by binding to the ATP‑binding site of the enzyme. It also blocks several other kinases such as VEGFR, FGFR, and PDGFR, thereby suppressing signaling pathways that drive tumor cell proliferation, survival, and angiogenesis. The combined effect leads to apoptosis of malignant cells and inhibition of disease progression.

Side Effects

Ponatinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Nausea
  • Diarrhea
  • Rash
  • Hypertension
  • Fatigue
  • Headache

Serious or Rare Side Effects

  • Arterial occlusive events (e.g., myocardial infarction, stroke)
  • Severe hypertension
  • Hepatotoxicity (elevated liver enzymes, hepatitis)
  • Pancreatitis
  • Cardiac failure
  • Venous thromboembolism

Precautions & Warnings

When prescribing ponatinib, clinicians should observe several precautionary measures to minimize risk.

  • Blood pressure monitoring: check and control hypertension regularly during treatment.
  • Liver function tests: assess hepatic enzymes before initiation and periodically thereafter.
  • Pancreatic enzymes: monitor amylase and lipase levels to detect pancreatitis early.
  • Cardiovascular risk assessment: avoid use in patients with recent arterial events or uncontrolled cardiovascular disease.
  • Drug interactions: review concomitant medications for CYP3A4 modulators and anticoagulants.
  • Store at room temperature: keep tablets in the original packaging, protect from moisture and excessive heat.

Avoid Interactions

Ponatinib interacts with several medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ponatinib exposure and toxicity.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels.
  • Anticoagulants (e.g., warfarin): heightened risk of bleeding when combined with ponatinib.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: ponatinib can exacerbate hypertension, requiring dose adjustments.
  • Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin concentrations, monitor for myopathy.
  • Other tyrosine kinase inhibitors: additive toxicity potential, monitor patient closely.
  • QT‑prolonging drugs: may increase risk of cardiac arrhythmias, observe ECG.

Frequently Asked Questions

Iclusig (ponatinib) is prescribed for patients with chronic myeloid leukemia or Philadelphia chromosome‑positive acute lymphoblastic leukemia who have not responded to, or cannot tolerate, earlier tyrosine kinase inhibitor therapies. It targets the BCR‑ABL protein, including resistant mutations, to help control disease progression.

Ponatinib blocks the activity of the BCR‑ABL tyrosine kinase by binding to its ATP‑binding pocket, which stops the enzyme from sending growth signals to cancer cells. It also inhibits several other kinases involved in tumor angiogenesis and survival, providing a broader anti‑cancer effect.

The dosage of Iclusig is individualized and determined by the prescribing physician based on the patient’s clinical condition, prior therapies, and tolerance. Only a qualified healthcare professional can set the appropriate dose and schedule.

The safety of ponatinib in pregnancy and lactation has not been established. It is classified as contraindicated or used only when the potential benefit justifies the risk. Women of childbearing potential should use effective contraception, and breastfeeding is generally discouraged.

To request Iclusig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iclusig is a third‑generation BCR‑ABL inhibitor that retains activity against the T315I mutation, which many earlier agents such as imatinib, dasatinib or nilotinib cannot overcome. This makes it a valuable option for patients whose disease has become resistant to those first‑ and second‑generation inhibitors.

Store Iclusig tablets at room temperature, below 25 °C, in the original container. Protect them from moisture, direct sunlight and excessive heat. Do not store in a refrigerator or freezer, and keep out of reach of children.

Iclusig is taken orally as a tablet, usually with a glass of water. It should be swallowed whole and not crushed or chewed. The exact timing and whether it is taken with food depend on the prescriber’s instructions.

The most serious adverse events include arterial occlusive events such as heart attack or stroke, severe hypertension, liver toxicity, pancreatitis, cardiac failure, and venous thromboembolism. Patients should be monitored closely for these conditions throughout treatment.

Iclusig should be avoided in patients with uncontrolled cardiovascular disease, recent arterial thrombotic events, severe hepatic impairment, or known hypersensitivity to ponatinib or any of its excipients. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ponatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT